MEDILINK Trademark

Trademark Overview


On Friday, January 21, 2022, a trademark application was filed for MEDILINK with the United States Patent and Trademark Office. The USPTO has given the MEDILINK trademark a serial number of 97232428. The federal status of this trademark filing is REGISTERED as of Tuesday, August 20, 2024. This trademark is owned by MediLink Therapeutics(Suzhou)Co.,Ltd.. The MEDILINK trademark is filed in the Pharmaceutical Products category with the following description:

Vaccines; Anti-cancer preparations; Biological preparations for the treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Chemical preparations for pharmaceutical or medical purposes, namely, for treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Cytostatics for pharmaceutical purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic preparations for medical purposes for detecting the presence of malignant, inflammatory and autoimmune disorders and conditions and tissue trauma in humans; Diagnostic reagents for ...
medilink

General Information


Serial Number97232428
Word MarkMEDILINK
Filing DateFriday, January 21, 2022
Status700 - REGISTERED
Status DateTuesday, August 20, 2024
Registration Number7482728
Registration DateTuesday, August 20, 2024
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, December 6, 2022

Trademark Statements


Description of MarkThe mark consists of the stylized wording "MEDILINK".
Goods and ServicesVaccines; Anti-cancer preparations; Biological preparations for the treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Chemical preparations for pharmaceutical or medical purposes, namely, for treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Cytostatics for pharmaceutical purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic preparations for medical purposes for detecting the presence of malignant, inflammatory and autoimmune disorders and conditions and tissue trauma in humans; Diagnostic reagents for medicinal use; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of antibody-drug conjugate that facilitate the delivery of pharmaceutical preparations; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicinal preparations for anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations, namely, elixirs for the treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Therapeutic pharmaceutical for the treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Tumor suppressing agents
Pseudo MarkMEDI LINK
Indication of Colors claimedColor is not claimed as a feature of the mark.
Translation of Words in MarkThe wording "MEDILINK" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, January 26, 2022
Primary Code005
First Use Anywhere DateThursday, June 9, 2022
First Use In Commerce DateThursday, June 9, 2022

Trademark Owner History


Party NameMediLink Therapeutics(Suzhou)Co.,Ltd.
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressSuzhou, Jiangsu 215000
CN

Party NameMediLink Therapeutics(Suzhou)Co.,Ltd.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressSuzhou, Jiangsu 215000
CN

Party NameMediLink Therapeutics(Suzhou)Co.,Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressSuzhou, Jiangsu 215000
CN

Trademark Events


Event DateEvent Description
Wednesday, January 26, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, January 25, 2022NEW APPLICATION ENTERED
Friday, October 28, 2022ASSIGNED TO EXAMINER
Tuesday, November 1, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 16, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 6, 2022PUBLISHED FOR OPPOSITION
Tuesday, December 6, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 31, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 18, 2023USE AMENDMENT FILED
Thursday, August 3, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, August 3, 2023STATEMENT OF USE PROCESSING COMPLETE
Tuesday, August 8, 2023SU - NON-FINAL ACTION - WRITTEN
Tuesday, July 18, 2023TEAS STATEMENT OF USE RECEIVED
Tuesday, August 8, 2023NON-FINAL ACTION E-MAILED
Tuesday, August 8, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, November 6, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Tuesday, July 2, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 2, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 15, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Monday, July 15, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, August 20, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, August 20, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, July 2, 2024ASSIGNED TO LIE
Monday, November 6, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Monday, January 8, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED